



0

16083

RECEIVED
MAY 01 2002
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/931,375	
	Filing Date	August 17, 2001	
	First Named Inventor	Matthew L. WARMAN et al	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission		Attorney Docket Number	38464-0004

RECEIVED
MAY 01 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08A (w/50 References)
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	HELLER EHRMAN WHITE & MCAULIFFE
Signature	<i>Patricia A. Granados</i> #33,683
Date	

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <div></div>			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



26633

PATENT TRADEMARK OFFICE



#10
CME
5/13/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38464-0004

Applicant: Matthew L. WARMAN et al. Confirmation No. 1602
Appl. No.: 09/931,375 Examiner: Unassigned
Filing Date: August 17, 2001 Art Unit: Unassigned
Title: REGULATOR GENE AND SYSTEM USEFUL FOR THE DIAGNOSIS
AND THERAPY OF OSTEOPOROSIS

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE STATEMENT

The relevance of documents A01-A50 are described in the present specification.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in

09/931,375

connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date:

March 29, 2002

By

Patricia D. Granados

HELLER EHRMAN WHITE &
MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, DC 20006
Telephone: (202) 912-2142
Facsimile: (202) 912-2020

Patricia D. Granados
Attorney for Applicant
Registration No. 33,683
Customer No. 26633



26633

PATENT TRADEMARK OFFICE

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/931,375
Filing Date	August 17, 2001
First Named Inventor	Matthew L. WARMAN et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38464-0004

Sheet 1 of 5

MAY 01 2002

RECEIVED

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A01	6,159,462		Matthews et al.	12/12/2000	
	A02	5,948,951		Gardiner et al.	9/7/99	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box ☐

PTO/SA/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, respondents are not required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	09/931,375
Filing Date	August 17, 2001
First Named Inventor	Matthew L. WARMAN et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38464-0004

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A03	S.J. HONG et al., "Novel inhibition of contractility by wortmannin in skeletal muscle", British Journal of Pharmacology, 1998, pp. 849-856, Vol. 124	
	A04	DAVID CHEN et al., "Molecular Cloning of Mouse Lrp7(Lr3) cDNA and Chromosomal Mapping of Orthologous Genes in Mouse and Human", Genomics, 1999, pp. 314-321, Vol. 55	
	A05	ANOUE COURSEAU et al., "Definition of the Minimal MEN1 Candidate Area Based on a 5-Mb Integrated Map of Proximal 11q13", Genomics, 1996, pp. 354-365, Vol. 37	
	A06	TREVOR C. DALE, "Signal transduction by the Wnt family of ligands", Biochem. J. 1998, pp. 209-223, Vol. 329	
	A07	YU DONG et al., "Molecular Cloning and Characterization of LR3, a Novel LDL Receptor Family Protein with Mitogenic Activity", Biochemical and Biophysical Research Communications, 1998, pp. 784-790, Vol. 251	
	A08	DAVID J. FIGUEROA et al., "Expression of the Type I Diabetes-associated Gene LRP5 in Macrophages, Vitamin A System Cells, and the Islets of Langerhans Suggests Multiple Potential Roles in Diabetes", The Journal of Histochemistry & Cytochemistry, 2000, pp. 1357-1368, Vol. 48, No. 10	
	A09	AKIRA FUJIMORI et al., "Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation", Mammalian Genome, 1998, pp. 1032-1035, Vol. 9	
	A10	GONG et al., "Posters: Linkage Mapping and Polymorphisms", Amer. J. Human. Gen., 1994, suppl: A86, Vol. 55	
	A11	YAOQIN GONG et al., "Osteoporosis-Pseudoglioma Syndrome, a Disorder Affecting Skeletal Strength and Vision, Is Assigned to Chromosome Region 11q12-13", Am. J. Hum. Genet., 1996, pp. 146-151, Vol. 59	
	A12	SEAN GRIMMOND et al., "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor", Genome Research, 1996, pp. 124-141, Vol. 6	
	A13	VINCENT GIGUERE et al., "Identification of a new class of steroid hormone receptors", Nature, January 7, 1988, pp. 91-94, Vol. 331	
	A14	LETICIA C. GUIDA et al., "Genetic mapping of the galanin-GMAP (Galn) gene to mouse Chromosome 19", Mammalian Genome, 1998, pp. 240-242, Vol. 9	
	A15	PATRICIA J. HEY et al., "Cloning of a novel member of the low-density lipoprotein receptor family", Gene, 1998, pp. 103-111, Vol. 216	
	A16	NICHOLAS KATSANIS et al., "Isolation of a paralog of the Doyme honeycomb retinal dystrophy gene from the multiple retinopathy critical region on 11q13", Hum. Genet., 2000, pp. 66-72, Vol. 106	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-20)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	09/931,375
Filing Date	August 17, 2001
First Named Inventor	Matthew L. WARMAN et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38464-0004

RECEIVED
MAY 01 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A17	DONG-HO KIM et al., "A New Low Density Lipoprotein Receptor Related Protein, LRP5, Is Expressed in Hepatocytes and Adrenal Cortex, and Recognizes Apolipoprotein E", J. Biochem., 1998, pp. 1072-1076, Vol. 124	
	A18	YI-PING LI et al., "Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification", Nature Genetic, December 1999, pp. 447-451, Vol. 23	
	A19	DITSA LEVANON et al., "cDNA Cloning of Human Oxysterol-Binding Protein and Localization of the Gene to Human Chromosome 11 and Mouse Chromosome 19", Genomics, 1990, pp. 65-74, Vol. 7	
	A20	AMANDA E. LEONARD et al., "cDNA cloning and characterization of human Δ^5 -desaturase involved in the biosynthesis of arachidonic acid", Biochem. J., 2000, pp. 719-724, Vol. 347	
	A21	JUNHAO MAO et al., "Low-Density Lipoprotein Receptor-Related Protein-5 Binds to Axin and Regulates the Canonical Wnt Signaling Pathway", Molecular Cell, April, 2001, pp. 801-809, Vol. 7	
	A22	SUSAN MATHEW et al., "Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kBp50, NF-kBp65, and Iyt-10 by fluorescence in situ hybridization", Oncogene, 1993, pp. 191-193, Vol. 8	
	A23	KOICHI MATSUO et al., "Fos/1 is a transcriptional target of c-Fos during osteoclast differentiation", Nature Genetics, February 2000, pp. 184-187, Vol. 24	
	A24	KEIKO TAMAI et al., "LDL-receptor-related proteins in Wnt signal transduction", Nature, September 28, 2000, pp. 530-35, Vol. 407	
	A25	HERMANN THIEN et al., Cloning and sequence analysis of the murine Gli3 cDNA", Viochimica et Biophysica Acta, 1996, pp. 267-269, Vol. 1307	
	A26	MARCEL WEHRLI et al., "Arrow encodes an LDL-receptor-related protein essential for Wingless signaling", Nature, September 28, 2000, Vol. 407	
	A27	ANDREAS WODARZ, "Mechanisms of WNT Signaling in Development", Annu. Rev. Cell Dev. Biol. 1998, pp. 59-88, Vol. 14	
	A28	MING-HONG XIE et al., "FGF-19, A Novel Fibroblast Growth Factor With Unique Specificity For FGFR4", Cytokine, October, 1999, pp. 729-735, Vol. 11, No. 10	
	A29	WUSHAN YIN et al., "Isolation of a Novel Latent Transforming Growth Factor-B Binding Protein Gene (LTBP-3)", The Journal of Biological Chemistry, 1995, pp. 1017-10160, Vol. 270, No. 17	
	A30	Evolutionary Homologs, Interactive Fly, Drosophila, http://strg.u-str.sbg.fr:7081/llied-d t /lk/interactive-fly/newgene/fz2-2.htm	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number 09/931,375
Filing Date August 17, 2001
First Named Inventor Matthew L. WARMAN et al.
Group Art Unit Unassigned
Examiner Name Unassigned
Attorney Docket Number 38464-0004

RECEIVED
MAY 01 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A31	Antibodies, http://www.researchd.com/miscabs/pro61068.htm , December 17, 1997	
	A32	Human Wnt genes, http://www.stnfrd.edu/~rnusse/wntgenes/humnwnt.html , May 23, 2001	
	A33	CHANG C., et al., "Xenopus GDF6, a new antagonist of noggin and a partner of BMPs", Development, August 1999, 126(15):3347-57	
	A34	FEDI P. et al., "Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling", J. Biol. Chem., July 1999, 274(27):19465-72	
	A35	ENOMOTO-IWAMOTO M., et al., "Hedgehog proteins stimulate chondrogenic cell differentiation and cartilage formation", J. Bone Miner Res. September 2000; 15(9):1659-68	
	A36	HATTORL A., et al., "Bone morphogenetic protein-2 is markedly synergistic with tumor necrosis factor in stimulating the production of nerve growth factor in fibroblasts", Biochem. Mol. Biol Int. May 1996; 38(6):1095-101	
	A37	HELVERING LM, et al., "Regulation of the promoters for the human bone morphogenetic protein 2 and 4 genes", Gene, October 3, 2000; 256(1-2):123-38	
	A38	HERDICK M. et al., "Carboxylic ester antagonists of 1alpha,25-dihydroxyvitamin D (3) show cell-specific actions", Chem Biol, November 2000; 7(11):885-94	
	A39	JIKKO A., et al., "Collagen integrin receptors regulate early osteoblast differentiation induced by BMP-2", J. Bone Miner Res., July 1999; 14(7):1075-83	
	A40	KIMURA J., et al., "Synergistic effects of FGF and non-ridge ectoderm on gene expression involved in the formation of the anteroposterior axis of the chick limb bud in cell culture", Dev. Growth Differ 2000, June 2000; 42(3):219-27	
	A41	KRUPNIK VE, et al., "Functional and structural diversity of the human Dickkopf gene family", Gene, October 1, 1999; 238(2):301-13	
	A42	LADHER RK et al., "Cloning and expression of the Wnt antagonists Sfrp-2 and Frzb during chick development", Dev Biol., February 15, 2000; 218(2):183-98	
	A43	LIU P., et al., "Regulation of osteogenic differentiation of human bone marrow stromal cells: interaction between transforming growth factor-beta and 1,25(OH)(2) vitamin D(3) In vitro", Calcif Tissue Int August 1999; 65(2):173-180	
	A44	MARZIA M. et al., "Decreased c-Src expression enhances osteoblast differentiation and bone formation", J. Cell Biol., October 16, 2000; 151(2):311-20	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	09/931,375
Filing Date	August 17, 2001
First Named Inventor	Matthew L. WARMAN et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38464-0004

RECEIVED
MAY 01 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A45	MONAGHAN AP, et al., "Dickkopf genes are co-ordinately expressed in mesodermal lineages", Mech Dev., September 1999; 87(1-2):45-56	
	A46	NAKASHMA K., et al., "Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300", Science, April 16, 1999; 284(5413):479-82	
	A47	PERA EM et al., "A direct screen for secreted proteins in Xenopus embryos identifies distinct activities for the Wnt antagonists Crescent and Frzb-1", Mech Dev., September 2000; 96(2):183-95	
	A48	SOTTILE V., et al., "Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone)", FEBS Lett, June 23, 2000; 475(3):201-4	
	A49	TORII Y., et al., "Synergistic effect of BMP-2 and ascorbate on the phenotypic expression of osteoblastic MC3T3-E1 cells", Mol. Cell Biochem., December 6, 1996; 165(1):25-9	
	A50	WILLETTE RN, et al., "BMP-2 gene expression and effects on human vascular smooth muscle cells", J. Vasc Res., March-April, 1999; 36(2):120-5	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.